Molecular Studies and Clinical Correlations in Human Prostatic Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.
| Condition |
|---|
|
Prostate Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only |
| Official Title: | Molecular Studies and Clinical Correlations in Human Prostatic Disease |
Human tissue, body fluids, and blood Fresh tissue will be obtained from patients undergoing a biopsy or surgical procedure as part of their standard therapy or as part of an investigational research protocol. Previously stored pathology specimens may also be used. Peripheral blood, bone marrow, urine, and other bodily fluids and samples will also be obtained as needed.
| Estimated Enrollment: | 2500 |
| Study Start Date: | April 1990 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.
Eligibility| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.
Inclusion Criteria:
Men with prostate conditions representing the following disease states:
- No Cancer Diagnosis
- Clinically Localized Disease
- Rising PSA
- Clinical Metastases: Noncastrate
- Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
- Signed informed consent
Exclusion Criteria:
-Patients without any prostate related problems.
Contacts and Locations| Contact: Susan Slovin, MD | 646-422-4470 | |
| Contact: James Eastham, MD | 646-422-4390 |
| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Principal Investigator: | Susan Slovin, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00578240 History of Changes |
| Other Study ID Numbers: | 90-040 |
| Study First Received: | December 19, 2007 |
| Last Updated: | June 6, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
|
benign Rising PSA Clinical Metastases 90-040 |
Additional relevant MeSH terms:
|
Prostatic Diseases Prostatic Neoplasms Genital Diseases, Male Genital Neoplasms, Male |
Urogenital Neoplasms Neoplasms by Site Neoplasms |
ClinicalTrials.gov processed this record on June 18, 2013